hrs4r
 I want to donate

The Metabolism and Cancer group adopts the view that cancer diseases are governed by metabolic reprogramming. Our laboratory pursues to understand the contribution of dysregulated metabolism in cancer initiation, drug resistance, and metastatic progression using laboratory-based experimental and computational tools through completion of clinical proof-of-efficacy in cancer patients.

Main lines of research
  1. Metabolism and cancer
  • Mechanistic understanding of metabolism-driven tumorigenesis
  • Metabolic mechanisms of cancer drug resistance
  • Identification of metabolic vulnerabilities as pharmacological targets for cancer therapy
  • Metabolomics and metabolic markers for early detection and clinical monitoring of cancer initiation, progression, and therapeutic resistance
  • Metabolo-epigenetics: Molecular aspects, computational modeling, and therapeutic development of precision medicine approaches

 

  1. Mitochondrial dynamics and cancer
  • Role of autophagy and mitochondria fussion/fission in the generation of cancer stem cells
  • Mitochondrial dynamics-targeted therapeutics for cancer therapy

 

  1. Natural biocompounds and cancer
  • Discovery and molecular characterization of natural biocompounds with anti-cancer properties
  • Pre-clinical development and clinical evaluation of natural biocompounds-based anti-cancer drugs

 

  1. Metabolo-immunotherapy
  • Identification of metabolic nodes and small-molecule metabolites essential for the regulation of immune checkpoints in cancer cells
  • Metabolic and dietary interventions to boost the efficacy of immune checkpoint inhibitors (ICIs).
  • Computational development and pre-clinical validation of in silico clinical trials platforms for testing new metabolo-immunotherapy approaches

 

  1. Computational systems biology in aging-driven cancer
  • Conceptual frameworks, stochastic tools, and wet-lab validation of metabolic and metabolo-epigenetic models of aging-driven cancer
Strategic objectives

To advance new metabolism-based anti-cancer therapeutics.

Publications

Romero A, Jantus-Lewintre E, García-Peláez B, Royuela A, Insa A, Cruz P, Collazo A, Pérez Altozano J, Vidal OJ, Diz P, Cobo M, Hernández B, Vázquez Estevez S, Benítez G, Guirado M, Majem M, Bernabé R, Ortega AL, Blasco A, Bosch-Barrera J, Jurado JM, García González J, Viteri S, Garcia Giron C, Massutí B, Lopez Martín A, Rodriguez-Festa A, Calabuig-Fariñas S, Molina-Vila MÁ, Provencio M

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.

MOLECULAR ONCOLOGY, 2021, 15, 43-56 dx.doi.org/10.1002/1878-0261.12832

Muñoz-Guardiola P, Casas J, Megías-Roda E, Solé S, Perez-Montoyo H, Yeste-Velasco M, Erazo T, Diéguez-Martínez N, Espinosa-Gil S, Muñoz-Pinedo C, Yoldi G, Abad JL, Segura MF, Moran T, Romeo M, Bosch-Barrera J, Oaknin A, Alfón J, Domènech C, Fabriàs G, Velasco G, Lizcano JM

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.

Autophagy, 2021, 17, 1-18 dx.doi.org/10.1080/15548627.2020.1761651

Tramonti A, Cuyàs E, Encinar JA, Pietzke M, Paone A, Verdura S, Arbusà A, Martin-Castillo B, Giardina G, Joven J, Vazquez A, Contestabile R, Cutruzzolà F, Menendez JA

Metformin Is a Pyridoxal-5'-phosphate (PLP)-Competitive Inhibitor of SHMT2.

Cancers, 2021, 13, 4009 dx.doi.org/10.3390/cancers13164009

Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer.

Cancers, 2021, 13, 4168 dx.doi.org/10.3390/cancers13164168

Verdura S, Cuyàs E, Ruiz-Torres V, Micol V, Joven J, Bosch-Barrera J, Menendez JA

Lung Cancer Management with Silibinin: A Historical and Translational Perspective.

Pharmaceuticals, 2021, 14, 559 dx.doi.org/10.3390/ph14060559

Menendez JA, Papadimitropoulou A, Vander Steen T, Cuyàs E, Oza-Gajera BP, Verdura S, Espinoza I, Vellon L, Mehmi I, Lupu R

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer.

Cancers, 2021, 13, 1132 dx.doi.org/10.3390/cancers13051132

Niksic M, Redondo-Sanchez D, Chang YL, Rodriguez-Barranco M, Exposito-Hernandez J, Marcos-Gragera R, Oliva-Poch E, Bosch-Barrera J, Sanchez MJ, Luque-Fernandez MA

The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study.

Bmc Cancer, 2021, 21, 1048-1048 dx.doi.org/10.1186/s12885-021-08801-9

Castañé H, Baiges-Gaya G, Hernández-Aguilera A, Rodríguez-Tomàs E, Fernández-Arroyo S, Herrero P, Delpino-Rius A, Canela N, Menendez JA, Camps J, Joven J

Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General Overview.

Biomolecules, 2021, 11, 473 dx.doi.org/10.3390/biom11030473

Cuyàs E, Gumuzio J, Lozano-Sánchez J, Segura-Carretero A, Verdura S, Bosch-Barrera J, Martin-Castillo B, Nonell-Canals A, Llebaria A, Cabello S, Serra C, Sanchez-Martinez M, Martin ÁG, Menendez JA

Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity.

Aging-Us, 2020, 12, 21057-21075 dx.doi.org/10.18632/aging.202154

Papadimitropoulou A, Vellon L, Atlas E, Steen TV, Cuyàs E, Verdura S, Espinoza I, Menendez JA, Lupu R

Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21, 7737 dx.doi.org/10.3390/ijms21207737
Competitive projects
Codi oficial: PID2019-104055GB-I00 Start date:01/06/2020 Data fi: 31/05/2023 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD Ajuda: 242,000 €
Codi oficial: CP20/00003 Start date:01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 202,500 €
Codi oficial: La Marató 201906-30 Start date:30/09/2020 Data fi: 29/09/2023 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 109,562.50 €
Transfer
Patents

Valiente Cortés Manuel, Priego Bendeck Neibla, Bosch Barrera Joaquim
MEANS FOR PREVENTING AND TREATING BRAIN METASTASIS
Número de publicació: EP20170382891
Data de publicació: 2019-06-26

Job offers

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

menu